Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for adults being performed through the North American Brain Tumor Consortium (NABTC), visit: <http://www.nabtc.org/>

**Newly Diagnosed Glioblastoma Multiforme**

- Phase II Study of PolyICLC plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme
- Phase I Study of R115777 plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme

**Newly Diagnosed Anaplastic Astrocytoma**

- A Phase I/III Randomized Study of Radiation Therapy and Temozolomide vs Radiation Therapy and BCNU vs Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma

**Newly Diagnosed Low-Grade Glioma**

- A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma

**Recurrent Tumor**

- Phase I/II Trial of CPT-11 and Temozolomide (Temodar) in Patients with Recurrent Malignant Glioma (NABTC 99-07)
- Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (NABTC 01-01)

**Recurrent Tumor, continued**

- ZD 1893 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAEDs (NABTC 00-01)
- A Phase I/II Trial of OSI-774 in Patients with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy
- A Phase II Trial of PolyICLC in Patients with Recurrent Anaplastic Glioma
- A Multicenter Phase I Study of TP-38 in Those Patients With Glioblastoma Multiforme [that has] Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection
- Phase II Trial of STI571 in Patients with Recurrent Meningioma
- Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PEQQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence

**Non-Chemotherapy Protocols**

- Assessment of Needs for a Complementary Medicine Program for Patients with Brain Tumors
- San Francisco Bay Area Adult Glioma Prognosis Study
- A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas (NABTC 01-07)
Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Consortium (PBTC), visit: <http://www.pbtc.org/>

Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors (PBTC 001)
This is a risk-adapted, multi-modality trial for patients under the age of 3 years who are newly diagnosed with medulloblastoma/PNET, metastatic ependymoma, or other primary intracranial embryonal tumors. For further details: <http://www.pbtc.org/public/PBTC001_HP_abstract.htm>

Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors (PBTC 003)
This is a phase I trial for patients 21 years of age or younger who have recurrent or progressive brain tumors. For further details: <http://www.pbtc.org/public/PBTC003_HP_abstract.htm>

Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors (PBTC 005)
This is a phase I trial for patients with recurrent or refractory pediatric brain tumors. For further details: <http://www.pbtc.org/public/PBTC005_HP_abstract.htm>

Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor-Prognosis Brainstem Glioma and Recurrent Intracranial Malignant Glioma (PBTC 006)
This is a phase I/II trial open to patients 3 to 21 years old. For further details: <http://www.pbtc.org/public/PBTC006_HP_abstract.htm>

A Phase I/II Trial of ZD1839 (Iressa™) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brain Stem Tumors (PBTC 007)
Children with newly diagnosed intrinsic brain stem gliomas (BSG) and incompletely resected supratentorial malignant gliomas (STMG) with residual tumor on imaging will be eligible for this study. For further details: <http://www.pbtc.org/public/PBTC007_HP_abstract.htm>

A Phase II Study of Oxaliplatin in Children with Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors, or Atypical Teratoid Rhabdoid Tumors after Failure of Initial Therapy (PBTC 010)
This is an open-label, single-agent, phase II study of oxaliplatin in pediatric patients with recurrent or refractory embryonal central nervous system tumors. For further details: <http://www.pbtc.org/public/PBTC010_HP_abstract.htm>

A Phase I Study of Cilengitide (EMB 121974) in Pediatric Patients with Refractory Brain Tumors (PBTC 012)
This is a phase I dose-escalation study of the anti-angiogenesis agent cilengitide, a potent and selective cyclized RGD pentapeptide antagonist of the integrins αvβ3 and αvβ5 in children with brain tumors refractory to standard therapy. For further details: <http://www.pbtc.org/public/PBTC012_HP_abstract.htm>

For further details about clinical trials for children being performed at UCSF, visit <http://www.cc.ucsf.edu/trials/peds_brain_toc.html>

Printed August 2004